Foamix Receives US Patent for Oleaginous Foam

Foamix Receives US Patent for Oleaginous Foam
Oleaginous Foams - Ideal Vehicles for Lipophilic and Water-Sensitive Drugs, such as Vitamin D, Retinoids and Lipophilic antibiotics
Rehovot, Israel (November 4, 2010) - Foamix Ltd., a clinical-stage specialty pharmaceutical company, that is developing proprietary dermatological and gynecologic topical foam products, today announced that the United States Patent and Trademark Office has issued US Patent 7,820,145, entitled  "Oleaginous Pharmaceutical and Cosmetic Foam". The patent covers novel foam formulations comprising hydrophobic solvents and or silicone oils as the main component. The claimed formulations can be water-free or alternatively can include up to 30% water.
Oleaginous foams are cosmetically-elegant and easy to use. They spread freely on the skin and absorb readily with a simple rub. They can be used as carriers for a variety of hydrophobic drugs, including drugs that degrade in the presence of water.
Foamix has incorporated a wide variety of drugs into its oleaginous foam, including various corticosteroids, vitamin D analogs, retinoids and lipophilic antibiotics.
This patent is the fifth to be issued to Foamix in the United States within the last 12 months, which collectively provides Foamix with protection for its emollient foam, hydrophilic waterless foam, iodine foam, oleaginous foam, and saccharide foam technologies. A further four issued US patents provide coverage for the Company's proprietary OilGelTM technology.
"We work hard to realize our unique development capabilities and to provide our products and our partners products with long-term market exclusivity" said Dov Tamarkin, PhD, CEO of Foamix. "This patent is an important component of Foamix's developing intellectual property portfolio covering a broad platform of topical delivery systems and their respective drug products."
About Foamix
Headquartered in Rehovot, Israel, Foamix Ltd. is a clinical-stage, privately held specialty pharmaceutical company, focused on the development of proprietary topical foam and OilGelTM products for prescription, OTC and cosmetic applications. Foamix creates advanced products with improved convenience, higher compliance and better efficacy, which are backed by an extensive patent portfolio. The company's development capabilities range from initial development of the formulations to scale-up, GMP manufacturing, preclinical and clinical studies.
Foamix partners with leading pharmaceutical companies, including Intendis (Bayer's dermatology company), Dr. Reddy's and Ferndale Laboratories.
Foamix has a strong in-house pipeline of dermatological and gynecological drugs. The Company's lead product, Topical Minocycline, is currently in Phase II clinical studies.
To date, Foamix has 9 issued patents in the United States, covering its foam and OilGelTM technology platforms. The company has an additional 150 applications and patents worldwide, of which more than 60 applications are filed in the U.S.
For additional information please see: www.foamix.co.il
Contact:
Sigal Maymon, Business Development, Foamix Ltd, +972-8-9316233 or [email protected]
Dov Tamarkin, CEO, Foamix Ltd, +972-8-9316233 or [email protected]

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.